S&P 500   5,095.11 (+0.16%)
DOW   39,186.90 (+0.30%)
QQQ   436.65 (-0.32%)
AAPL   182.54 (-0.99%)
MSFT   410.16 (-0.36%)
META   483.80 (-0.48%)
GOOGL   143.82 (-0.19%)
AMZN   174.45 (-0.07%)
TSLA   192.02 (-2.73%)
NVDA   788.25 (+0.37%)
NIO   5.45 (-6.84%)
AMD   176.02 (-3.21%)
BABA   75.98 (-0.18%)
T   16.82 (+1.39%)
F   12.14 (+0.17%)
MU   85.61 (-0.35%)
CGC   3.37 (+0.00%)
GE   153.37 (+1.12%)
DIS   107.69 (+0.05%)
AMC   4.46 (+0.90%)
PFE   27.80 (+0.91%)
PYPL   59.26 (+1.56%)
XOM   104.00 (-0.73%)
S&P 500   5,095.11 (+0.16%)
DOW   39,186.90 (+0.30%)
QQQ   436.65 (-0.32%)
AAPL   182.54 (-0.99%)
MSFT   410.16 (-0.36%)
META   483.80 (-0.48%)
GOOGL   143.82 (-0.19%)
AMZN   174.45 (-0.07%)
TSLA   192.02 (-2.73%)
NVDA   788.25 (+0.37%)
NIO   5.45 (-6.84%)
AMD   176.02 (-3.21%)
BABA   75.98 (-0.18%)
T   16.82 (+1.39%)
F   12.14 (+0.17%)
MU   85.61 (-0.35%)
CGC   3.37 (+0.00%)
GE   153.37 (+1.12%)
DIS   107.69 (+0.05%)
AMC   4.46 (+0.90%)
PFE   27.80 (+0.91%)
PYPL   59.26 (+1.56%)
XOM   104.00 (-0.73%)
S&P 500   5,095.11 (+0.16%)
DOW   39,186.90 (+0.30%)
QQQ   436.65 (-0.32%)
AAPL   182.54 (-0.99%)
MSFT   410.16 (-0.36%)
META   483.80 (-0.48%)
GOOGL   143.82 (-0.19%)
AMZN   174.45 (-0.07%)
TSLA   192.02 (-2.73%)
NVDA   788.25 (+0.37%)
NIO   5.45 (-6.84%)
AMD   176.02 (-3.21%)
BABA   75.98 (-0.18%)
T   16.82 (+1.39%)
F   12.14 (+0.17%)
MU   85.61 (-0.35%)
CGC   3.37 (+0.00%)
GE   153.37 (+1.12%)
DIS   107.69 (+0.05%)
AMC   4.46 (+0.90%)
PFE   27.80 (+0.91%)
PYPL   59.26 (+1.56%)
XOM   104.00 (-0.73%)
S&P 500   5,095.11 (+0.16%)
DOW   39,186.90 (+0.30%)
QQQ   436.65 (-0.32%)
AAPL   182.54 (-0.99%)
MSFT   410.16 (-0.36%)
META   483.80 (-0.48%)
GOOGL   143.82 (-0.19%)
AMZN   174.45 (-0.07%)
TSLA   192.02 (-2.73%)
NVDA   788.25 (+0.37%)
NIO   5.45 (-6.84%)
AMD   176.02 (-3.21%)
BABA   75.98 (-0.18%)
T   16.82 (+1.39%)
F   12.14 (+0.17%)
MU   85.61 (-0.35%)
CGC   3.37 (+0.00%)
GE   153.37 (+1.12%)
DIS   107.69 (+0.05%)
AMC   4.46 (+0.90%)
PFE   27.80 (+0.91%)
PYPL   59.26 (+1.56%)
XOM   104.00 (-0.73%)
NASDAQ:OPGN

OpGen (OPGN) Stock Price, News & Analysis

$0.42
+0.00 (+0.95%)
(As of 03:08 PM ET)
Today's Range
$0.42
$0.44
50-Day Range
$0.26
$0.46
52-Week Range
$0.17
$3.84
Volume
76,446 shs
Average Volume
191,552 shs
Market Capitalization
$4.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

OPGN stock logo

About OpGen Stock (NASDAQ:OPGN)

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

OPGN Stock Price History

OPGN Stock News Headlines

OpGen (NASDAQ:OPGN) Research Coverage Started at StockNews.com
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
OpGen Inc OPGN
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
OpGen surges after announcing private placement
OpGen, Inc. (OPGN) interactive stock chart – Yahoo Finance
Why Is OpGen (OPGN) Stock Up 540% Today?
Earnings Outlook For OpGen
See More Headlines
Receive OPGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2023
Today
2/23/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:OPGN
Employees
85
Year Founded
N/A

Profitability

Net Income
$-37,280,000.00
Net Margins
-852.18%
Pretax Margin
-852.18%

Debt

Sales & Book Value

Annual Sales
$2.61 million
Book Value
$2.61 per share

Miscellaneous

Free Float
9,881,000
Market Cap
$4.21 million
Optionable
Not Optionable
Beta
-0.90
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Oliver Schacht Ph.D. (Age 53)
    CEO, President & Director
    Comp: $408k
  • Mr. Albert Weber (Age 61)
    CFO & Corporate Secretary
    Comp: $317.5k
  • Mr. Johannes BacherMr. Johannes Bacher (Age 55)
    Chief Operating Officer
    Comp: $300k
  • Mr. Vadim Sapiro (Age 53)
    Chief Information Officer
    Comp: $300k
  • Ms. Faranak Atrzadeh
    Chief Marketing & Scientific Affairs Officer
  • Dr. Theo deVos
    MD & CEO of Ares Genetics














OPGN Stock Analysis - Frequently Asked Questions

Should I buy or sell OpGen stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OPGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPGN, but not buy additional shares or sell existing shares.
View OPGN analyst ratings
or view top-rated stocks.

How have OPGN shares performed in 2024?

OpGen's stock was trading at $0.42 at the beginning of the year. Since then, OPGN shares have increased by 1.0% and is now trading at $0.4240.
View the best growth stocks for 2024 here
.

Are investors shorting OpGen?

OpGen saw a decrease in short interest in the month of January. As of January 31st, there was short interest totaling 23,700 shares, a decrease of 23.8% from the January 15th total of 31,100 shares. Based on an average daily volume of 223,100 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.2% of the shares of the company are short sold.
View OpGen's Short Interest
.

When is OpGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our OPGN earnings forecast
.

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) released its earnings results on Thursday, August, 10th. The medical research company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.22. The medical research company earned $0.74 million during the quarter, compared to analyst estimates of $0.90 million. OpGen had a negative trailing twelve-month return on equity of 316.30% and a negative net margin of 852.18%. During the same quarter last year, the business posted ($2.60) EPS.

When did OpGen's stock split?

Shares of OpGen reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of OpGen own?
When did OpGen IPO?

(OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

How do I buy shares of OpGen?

Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPGN) was last updated on 2/23/2024 by MarketBeat.com Staff